The DAPT Study is a double blind randomized controlled trial intended to determine the
appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second
anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet
therapy to protect patients from stent thrombosis and major adverse cardiovascular and
cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents.
Similar analysis will be conducted in a smaller cohort of bare metal coronary stent - treated
subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Baim Institute for Clinical Research Harvard Clinical Research Institute
Collaborators:
Abbott Boston Scientific Corporation Bristol-Myers Squibb Cordis Corporation Daiichi Sankyo Inc. Daiichi Sankyo, Inc. Eli Lilly and Company Medtronic Sanofi-Synthelabo